Download

Mobile

Desktop

Download now

View more versions

About us

English
中文繁體
中文简体

Markets
Products
News
Moo Community
- Feed
  
  Find inspiration for your next move
- Topics
  
  Discuss hot topics with like-minded traders
Learn
Investing
- Investment Choices
  
  Explore investment products
  Cash Sweep
  
  Stocks
  
  Fractional Shares
  
  ETFs
  
  Options
  
  Margin Trade
- Features
  
  See our powerful trading features in action
  Charts
  
  Stock Analysis
  
  Level 2 Data
  
  Nasdaq Market Depth
- Pricing
  
  Transparent fees, no account minimums

Open Account

Financial services in the moomoo app are provided by Moomoo Financial Inc. You will be redirected to Moomoo Financial Inc's web domain, where the account application pages are hosted.

Account Info

Log Out

English

Back

Markets
Products
News
Moo Community
- Feed
  
  Find inspiration for your next move
Learn
Investing
- Investment Choices
  - Cash Sweep
  - Stocks
  - Fractional Shares
  - ETFs
  - Options
  - Margin Trade
- Features
- Pricing
  
  Transparent fees, no account minimums

English
中文繁體
中文简体

Dark
Light

Download

Back to the Top

野村：重申中国生物制药(01177)“买入”评级目标价降至6.16港元

Nomura: Reiterates China Biopharmaceutical's (01177) “Buy” Rating Target Price Reduction to HK$6.16

Zhitong Finance · Mar 15 04:00

SINO BIOPHARM +1.44%

野村将中生制药2023及2024财年的销售预测分别下调5.6%和7.3%。

智通财经APP获悉，野村发布研究报告称，预计中国生物制药(01177) 去年下半年的盈利将在同比基数较低的基础上实现高增长，又预计集团2024财年有更多业务发展交易、出售非核心子公司及新药上市。另将中生制药2023及2024财年的销售预测分别下调5.6%和7.3%，而盈测则各调低12.2%。不过，该行重申“买入”评级，目标价由6.63港元降至6.16港元。

Nomura lowered Chusei Pharmaceutical's sales forecast for fiscal year 2023 and 2024 by 5.6% and 7.3%, respectively.

The Zhitong Finance App learned that Nomura released a research report saying that it is expected that China Biopharmaceutical (01177)'s profit in the second half of last year will achieve high growth on a low year-on-year basis, and the Group also expects more business development transactions, sale of non-core subsidiaries and new drug listings in the 2024 fiscal year. In addition, Zhongsheng Pharmaceutical's sales forecasts for the 2023 and 2024 fiscal years were lowered by 5.6% and 7.3%, respectively, while profit estimates were lowered by 12.2%, respectively. However, the bank reiterated its “buy” rating and the target price was reduced from HK$6.63 to HK$6.16.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more

Risk Disclaimer

This page is machine-translated. Moomoo tries to improve but do not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeline for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.

In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).

In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.

In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our website https://www.moomoo.com/au.

In Canada, order-execution only services available through the moomoo app are provided by Moomoo Financial Canada Inc., regulated by the Canadian Investment Regulatory Organization (CIRO).

In Malaysia, investment products and services available through the moomoo app are offered through Moomoo Securities Malaysia Sdn. Bhd. ("Moomoo MY")regulated by the Securities Commission of Malaysia (SC). Moomoo Securities Malaysia Sdn. Bhd. is a Capital Markets Services Licence (License No. eCMSL/A0397/2024) holder. This advertisement has not been reviewed by the SC.

Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc., and Moomoo Securities Malaysia Sdn. Bhd. are affiliated companies.

Got it

Risk Disclaimer

Got it

Statement

This page is machine-translated. Moomoo tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.

Write a comment

0 0

LikeLoveLaughing CryRespectEmmSadAngry

Tap to Select a Mood

分享到weixin
分享到qq
分享到facebook
分享到twitter
分享到微博
粘贴板

Use the share button in your browser
to share the page with your friends

Tap here to share

No comments yet. Write one.

About moomoo

Terms & Conditions

Licensed Entities*

Your Privacy Choices

Careers / Contact:

hr@us.moomoo.com

The moomoo app is an online trading platform offered by Moomoo Technologies Inc. Securities, brokerage products and related services available through the moomoo app are offered by including but not limited to the following brokerage firms: Moomoo Financial Inc. regulated by the U.S. Securities and Exchange Commission (SEC), Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS), Futu Securities International (Hong Kong) Limited regulated by the Securities and Futures Commission of Hong Kong (SFC), Moomoo Financial Canada Inc. regulated by the Canadian Investment Regulatory Organization (CIRO) and Futu Securities (Australia) Ltd regulated by the Australian Securities and Investments Commission (ASIC).

For further information about Moomoo Financial Inc., please visit Financial Industry Regulatory Authority (FINRA)’s BrokerCheck. Brokerage accounts with Moomoo Financial Inc. are protected by the Securities Investor Protection Corporation (SIPC). Moomoo Financial Inc. is a member of Securities Investor Protection Corporation (SIPC), which protects securities customers of its members up to $500,000 (including $250,000 for claims for cash). It is important to understand that SIPC protects customer accounts against losses caused by the financial failure of the broker-dealer, but not against an increase or decrease in the market value of securities in customers' accounts. SIPC does not protect against market risk, which is the risk inherent in a fluctuating market. For further information about SIPC coverage for accounts with Moomoo Financial Inc., see www.sipc.org or request an explanatory brochure from Moomoo Financial Inc.

Options trading entails significant risk and is not appropriate for all customers. It is important that investors read Characteristics and Risks of Standardized Options before engaging in any options trading strategies. Options transactions are often complex and may involve the potential of losing the entire investment in a relatively short period of time. Certain complex options strategies carry additional risk, including the potential for losses that may exceed the original investment amount. Supporting documentation for any claims, if applicable, will be furnished upon request.

Investments in stocks, options, ETFs and other instruments are subject to risks, including possible loss of the amount invested. The value of investments may fluctuate and as a result, clients may lose the value of their investment. Past performance should not be viewed as an indicator of future results.

Margin trading involves interest charges and heightened risks, including the potential to lose more than invested funds or the need to deposit additional collateral. Before trading on margin, customers are advised to determine whether this type of trading is appropriate for them in light of their respective investment objective, experience, risk tolerance and financial situation.

Free trading refers to $0 commissions for Moomoo Financial Inc. self-directed individual cash or margin brokerage accounts of U.S. residents that trade U.S. listed securities via mobile devices or Web. Relevant SEC & FINRA fees may apply. For details, please see Commission and Fees.

All types of investments are risky and investors may suffer losses. Past performance of investment products does not guarantee future results. Electronic trading also poses risks to investors. The responsiveness of the trading system may vary due to market conditions, system performance, and other factors. Account access and trade execution may be affected by factors such as market volatility.

No content on the website shall be considered as a recommendation or solicitation for the purchase or sale of securities, futures, or other financial products. All information and data on the website are for reference only and no historical data shall be considered as the basis for predicting future trends.

Information contained on this website is general in nature and has been prepared without any consideration of customers’ investment objectives, financial situations or needs. Customers should consider the appropriateness of the information having regard to their personal circumstances before making any investment decisions.

Investment products are not insured by the Federal Deposit Insurance Corporation (FDIC) or guaranteed by a bank, and may decline in value.

The services and products offered on the website are subject to applicable laws and regulations, as well as relevant service terms and policies. The services and products are not available to all customers or in all geographic areas or in any jurisdiction where it is unlawful for us to offer such services and products.

野村：重申中国生物制药(01177)“买入”评级 目标价降至6.16港元

Nomura: Reiterates China Biopharmaceutical's (01177) “Buy” Rating Target Price Reduction to HK$6.16

Risk Disclaimer

Statement

野村：重申中国生物制药(01177)“买入”评级目标价降至6.16港元